LT3180314T - Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas - Google Patents

Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas

Info

Publication number
LT3180314T
LT3180314T LTEPPCT/NL2015/050555T LT15767345T LT3180314T LT 3180314 T LT3180314 T LT 3180314T LT 15767345 T LT15767345 T LT 15767345T LT 3180314 T LT3180314 T LT 3180314T
Authority
LT
Lithuania
Prior art keywords
preparation
production
intermediate compounds
synthetic intermediate
tetrahydroquinoline derivatives
Prior art date
Application number
LTEPPCT/NL2015/050555T
Other languages
English (en)
Lithuanian (lt)
Inventor
John Ford
Johannes Paulus Gerardus Seerden
Amandine LEDRU
Original Assignee
Newamsterdam Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51429345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3180314(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newamsterdam Pharma B.V. filed Critical Newamsterdam Pharma B.V.
Publication of LT3180314T publication Critical patent/LT3180314T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEPPCT/NL2015/050555T 2014-08-12 2015-07-29 Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas LT3180314T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Publications (1)

Publication Number Publication Date
LT3180314T true LT3180314T (lt) 2022-11-10

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/NL2015/050555T LT3180314T (lt) 2014-08-12 2015-07-29 Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas

Country Status (27)

Country Link
US (1) US10112904B2 (cg-RX-API-DMAC7.html)
EP (2) EP3180314B1 (cg-RX-API-DMAC7.html)
JP (1) JP6670310B2 (cg-RX-API-DMAC7.html)
KR (1) KR102572626B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108558B (cg-RX-API-DMAC7.html)
AR (1) AR101509A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015302407B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017002873B1 (cg-RX-API-DMAC7.html)
CA (1) CA2958040C (cg-RX-API-DMAC7.html)
CL (1) CL2017000367A1 (cg-RX-API-DMAC7.html)
DK (1) DK3180314T3 (cg-RX-API-DMAC7.html)
EA (1) EA034357B1 (cg-RX-API-DMAC7.html)
ES (1) ES2926775T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221061T1 (cg-RX-API-DMAC7.html)
HU (1) HUE059947T2 (cg-RX-API-DMAC7.html)
IL (1) IL250525B (cg-RX-API-DMAC7.html)
LT (1) LT3180314T (cg-RX-API-DMAC7.html)
MA (1) MA40378B1 (cg-RX-API-DMAC7.html)
MX (1) MX367908B (cg-RX-API-DMAC7.html)
PL (1) PL3180314T3 (cg-RX-API-DMAC7.html)
PT (1) PT3180314T (cg-RX-API-DMAC7.html)
RS (1) RS63575B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701077XA (cg-RX-API-DMAC7.html)
SI (1) SI3180314T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200385T1 (cg-RX-API-DMAC7.html)
TW (1) TWI691490B (cg-RX-API-DMAC7.html)
WO (1) WO2016024858A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212483A1 (en) 2021-03-05 2022-09-09 Newamsterdam Pharma B.V. Obicetrapib for treatment of dementias
AU2022320869A1 (en) 2021-07-26 2024-02-01 Newamsterdam Pharma B.V. Treatment of his hyporesponders
CA3242880A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. COMBINATION OF OBITECRAPIB AND SGLT2 INHIBITOR
EP4551567A1 (en) 2022-07-05 2025-05-14 NewAmsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024042061A1 (en) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2024165395A1 (en) 2023-02-07 2024-08-15 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
WO2025146262A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
KR100639745B1 (ko) * 2001-04-30 2006-10-30 화이자 프로덕츠 인크. Cetp 억제제 제조 방법
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200808731A (en) * 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法

Also Published As

Publication number Publication date
AU2015302407A1 (en) 2017-03-02
EP3180314B1 (en) 2022-06-22
RS63575B1 (sr) 2022-10-31
SG11201701077XA (en) 2017-03-30
MA40378A (fr) 2017-06-21
BR112017002873B1 (pt) 2023-03-28
DK3180314T3 (da) 2022-08-29
BR112017002873A8 (pt) 2022-11-08
AU2015302407B2 (en) 2019-09-19
MA40378B1 (fr) 2022-10-31
MX367908B (es) 2019-09-11
EA034357B1 (ru) 2020-01-30
EP3180314A1 (en) 2017-06-21
CL2017000367A1 (es) 2018-02-09
ES2926775T3 (es) 2022-10-28
WO2016024858A1 (en) 2016-02-18
TWI691490B (zh) 2020-04-21
US10112904B2 (en) 2018-10-30
SI3180314T1 (sl) 2022-11-30
AR101509A1 (es) 2016-12-21
US20170267640A1 (en) 2017-09-21
SMT202200385T1 (it) 2022-11-18
IL250525B (en) 2019-08-29
KR102572626B1 (ko) 2023-08-30
KR20170102204A (ko) 2017-09-08
CN107108558B (zh) 2019-11-19
EA201790364A1 (ru) 2017-07-31
CA2958040C (en) 2022-09-13
HRP20221061T1 (hr) 2022-11-25
PL3180314T3 (pl) 2022-11-21
IL250525A0 (en) 2017-03-30
MX2017001930A (es) 2018-03-01
CN107108558A (zh) 2017-08-29
TW201613868A (en) 2016-04-16
PT3180314T (pt) 2022-09-02
EP4083022A1 (en) 2022-11-02
JP6670310B2 (ja) 2020-03-18
CA2958040A1 (en) 2016-02-18
BR112017002873A2 (pt) 2018-07-17
HUE059947T2 (hu) 2023-01-28
JP2017524742A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
HUE042409T2 (hu) Eljárás diaril-tiohidantoin vegyület elõállítására
LT3180314T (lt) Sintetinių tarpinių junginių, skirtų tetrahidrochinolino darinių gamybai, gavimo būdas
HUE059158T2 (hu) Eljárás pridopidin elõállítására
BR112017003051A2 (pt) composto, método para produção de material magnético
HUE050974T2 (hu) Eljárás pirimidinszulfamid-származékok elõállítására
PL3142785T3 (pl) Sposób wytwarzania alkenoli i ich zastosowanie do wytwarzania 1,3- butadienu
HUE042349T2 (hu) Eljárás diariltiohidantoin vegyület elõállítására
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
HUE050553T2 (hu) Eljárás A módosulatú kalkobutrol kristályos alakjának elõállítására
SI3160985T1 (sl) Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L- fenilalaninamida
HRP20181805T1 (hr) Postupak za proizvodnju poligvanidina
BR112016027819A2 (pt) Processo de preparação de derivados de tiazole
BR112016027556A2 (pt) métodos de preparação de um composto
ZA201704196B (en) Method for the production of praziquantel
ITBA20140018A1 (it) Macchinario per la produzione di stracciatella
GB2564185B (en) Process for the preparation of derivatives of benzodioxole
FI20146104A7 (fi) Prosessi spirosyklisten substituoitujen bentsofurokinolitsiinien valmistamiseksi
IL262889B (en) Process for the manufacture of 6-alkynyl-pyridine derivatives
ZA201701100B (en) Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
TH1501005819A (th) วิธีการสำหรับการผลิต 2,7-ออกทาไดอีน-1-ออล
TH1501006120A (th) กระบวนการสำหรับการผลิตสารประกอบไซโคลเฮกซาโนน
TH1601002609A (th) กระบวนการทำอะดามันทานาไมด์
TH1601000728A (th) แคปซูลสำหรับการผลิตเครื่องดื่ม
TH1501007345A (th) กระบวนการเพื่อการเตรียมโทโคฟีรอลเข้มข้น